Chairman & Chief Executive Officer (also interim CFO/Principal Financial Officer as of early 2026), Agenus
Search every verified Garo Armen interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Garo Armen, chairman and chief executive officer of Agenus, participated in a company conference call on July 13, 2026, regarding financing and the ROBBIN trial strategy. During the call, he introduced two guest investigators, Professor Miriam Chilapi and Dr. Christi, who discussed neo-adjuvant immunotherapy approaches for colon cancer. Armen also addressed questions about the French AAC program, stating that the company is collecting real-world outcome data under the program's guidance.
“I would mandate that companies make compromises in terms of reducing their level of greed, and allow for access anywhere in the world for drugs that deserve to get to patients. And of course in doing this, by the way, the obstacles are not by the originator countries that provide these drugs, but also countries that ar...”
“I'm not a believer in that because there is so much abuse, or wasted monies on research. There is this clubishness of research institutions that used to be much worse in the past, like the NCI, National Cancer Institute, NIH, National Institutes of Health, where an exorbitant amount of research money has went into subs...”
“The biggest obstacle is the standard line that it's not possible. And of course something is not possible until you do it and demonstrate that it is possible. And so I think biases that are pervasive amongst people globally that if there is no precedence for something that the default position is that it should not be...”
“Take advice from people but decisions are made not by a committee. Successful decisions are made by listening to groups of people, getting their input, but at the end of the day, a successful decision needs to be made by an individual.”
“As we enter 2026, we're doing so with a greater clarity. And that means clarity means lack of uncertainty. Certainly some of the uncertainty that we experienced in the second half of last year with delayed closing of one of our important transactions. So with the recent closing of our collaboration transaction which in...”
“Priorities for 2026 are very clear. Number one, we've seen a growing interest and I must say substantially growing interest in our nation programs, namely the paid nation France and outside of France. It is our moral responsibility to make sure that that demand is met honorably and with compliance. Number two priority...”
“In 2025 the botbal program reached a number of important inflection points. Clinical data now span more than 1,200 patients treated across nine tumor types from the most refractory settings to earlier localized disease. These findings continue to reinforce the fact that a clear trend is emerging in a significant number...”
“As we move into 2026, our priorities are clear. We will expand patient access to botbal including through France's reimbursed AAC pathway and Agenus paid named patient program available in approximately 30 countries that allow self-pay or pay with special insurance that has a patient's ability to access a not yet appro...”
“My number one advice is never do anything because you want to make a lot of money. Now, making a lot of money, there's nothing wrong with it. Okay? Not anything wrong with it. However, if that's your number one objective, then it's not good. Your number one objective must be to deliver something that addresses a need i...”
“Well in in biotech um biotech is a tough business because it's heavily regulated but by people who are not qualified to do anything. And so that's one of the reasons innovation in biotech is slower whereas innovation in technology has been at a an incredible pace and uh we have a lot to learn from that of course but um...”
“drug development uh has unfortunately become such a bureaucratic process and even though regulatory agencies take comfort in the fact that they have all these procedures that are designed to protect patients but overregulation which is what we're experiencing right now ends up hurting patients by delaying the developme...”
“We've approved drugs uh that provide only four, five, six weeks of extension to life, but at a huge cost to patients. Because during those four, five, 6 weeks of extension to life, quality of life is horrible for these patients. It's almost inhumane to treat these patients with drugs that regulatory agencies and compan...”
“In our trials Roger approximately 20% of the patients that are near their deathbed are looking like they will live a normal life for an extended period of time. What does that mean? I'm talking about well over two years. As we follow these patients, we look at the survival tale. And when you look at that, at least 20%...”
“The most recent drug that was approved about a year ago is a drug that extends life by merely two months with no cures in sight. And the drug prior to that that was approved is another drug that extended the life for at that time by six weeks at a significant cost in quality of life to the patient.”
“every single cancer of an individual is a different disease. In other words, we say for example XYZ individual has lung cancer. That doesn't mean that his or her lung cancer is the same as somebody else's lung cancer. It simply means that it's a mutation of the tissue, mutation of the cell that is in the lung, not beca...”
Agenus Conference Call on Financing and ROBBIN Trial Strategy | July 13, 2026. Twitter - https://x.com/i101yt If you find our work ...
In this episode, Princess Dina sits down with Dr. Garo Armen, Chairman and CEO of Agenus, to explore the promise and limits of ...
Welcome to the Bridging Minds FSU x ASUE Podcast Series on Armenian Entrepreneurship, where we spotlight innovation, resilience, and entrepreneurship across borders. Hosted by Madison Miller, Research Assistant at Florida State University’s Jim Moran College of Entrepreneurship, this episode features Garo Armen, the CEO of Agenus and chairman of the Children of Armenia Fund. Together, we explore his entrepreneurial journey, the challenges he’s overcome, and the meaningful impact he’s creating through innovation and purpose. This podcast series was funded by the grant SAM10024CA0023-M001 “Pro…
In this recorded Agenus stakeholder webcast, Garo Armen is joined by leading oncology experts to discuss expanding patient access to next-generation immunotherapy and Agenus’ momentum entering 2026. Highlights include a clinical discussion with Robin Jones (Royal Marsden Hospital) on sarcoma and immunotherapy, the expansion of France’s reimbursed AAC early-access pathway to sarcoma and ovarian cancer, and an update on Agenus’ strategic collaboration with Zydus Lifesciences, strengthening U.S.-based biologics manufacturing. The webcast also covers growing global physician demand, real-world ev…
Join us for Agenus’ End-of-Year 2025 Webcast featuring leading GI oncologists and a powerful caregiver-physician story that brings the BOT/BAL journey to life. Hear how immunotherapy expectations in MSS colorectal cancer are shifting, get an inside look at the global Phase 3 BATTMAN trial, and learn how innovative approaches may change the path forward for patients. Featuring: • Dr. Christopher Lieu — evolving role of IO in CRC • Dr. Jonathan Loree — Phase 3 global trial momentum • Dr. Benny Johnson — a personal early-onset CRC journey and clinical-trial decision-making Moderated by Garo Arm…
This October 2025 Stakeholder Briefing features new data from ESMO 2025 and international access milestones advancing Agenus' immunotherapy combination, botensilimab (BOT) and balstilimab (BAL) for patients with hard-to-treat cancers. Featured Speakers: • Dr. Michael Gordon, Chief Medical Officer, HonorHealth Research Institute – reviews updated Phase 1b pan-tumor data presented at ESMO 2025, spanning more than 400 patients with refractory solid tumors. • Professor Alexander Eggermont, global immuno-oncology expert and former Director General of Gustave Roussy Cancer Center (France) – discuss…
Dr. Garo Armen is a renowned Armenian-American scientist, entrepreneur, and philanthropist. As Chairman and CEO of Agenus Inc., which he co-founded in 1994, he has become one of the leading figures in the global biotechnology sector. Beyond his corporate leadership, Dr. Armen is best known for founding the Children of Armenia Fund (COAF) — a transformative initiative that has invested over $100 million to revitalize rural communities across Armenia. A recipient of the Ellis Island Medal of Honor, the Sabin Humanitarian Award, and the Prime Minister’s Medal of Honor of Armenia, Dr. Armen embodi…
ATOM (Advanced Tomorrow) Dialogues Dr. Garo Armen and Nouneh Sarkissian www.advancedtomorrow.com.
Roger talks with Dr. Garo H. Armen on if Big Pharma and some professionals in the medical industry are suppressing research and findings on a potential cure for cancer, natural remedies, and more. Learn more about your ad choices. Visit megaphone.fm/adchoices (https://megaphone.fm/adchoices)
Garo Armen is the Chairman and CEO of Agenus, a pioneering biotech company advancing cancer treatment. He is founder of the Children of Armenia Fund (COAF), an organization dedicated to revitalizing rural Armenia by building modern schools, healthcare facilities, and community programs, significantly enhancing the quality of life and opportunities for local children and families. Armenian American Forum 2025 https://tennessee.hyelandproject.com/...
Sign in to search the full transcript archive, filter by topic, and access every quote from Garo Armen.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →